Therefore, we highlight that lung‐cancer‐related STMs (NSE, CEA, CA125, CA153, CYFRA21‐1, SCC) could be potential predictors of resistance and prognosis of lung cancer treated with targeted therapy. This evidence concerns the gene CEACAM5 and lung carcinoma.